Introduction {#Sec1}
============

The term "taxonomy" is used to describe the classification of various things, so the term "drug taxonomy" refers to the science of listing and describing drugs, according to various properties, in a manner which allows easy comprehension and understanding of their usage.

Traditionally, only pharmaceutical properties (e.g., chemical structure and pharmacodynamic and pharmacokinetic characteristics) have been used to separate drugs into various groups. Increasingly, however, the end user (i.e., the patient's or community's perspective) is considered when studying pharmacology \[[@CR1], [@CR2]\]. In the present work, we provide a balanced, syncretic approach to insulin taxonomy, using both patient-centered and pharmacokinetic aspects, to craft a number-based classification of insulin regimes.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Current Insulin Taxonomy {#Sec2}
========================

Endocrinology and diabetology textbooks provide comprehensive coverage of various insulin preparations and then utilize these to discuss different insulin regimes. The current American Diabetes Association (ADA)/European Association for Study of Diabetes (EASD) 2015 guidelines use the terms "basal," "basal plus," "premixed," "split-mix," and "intensive" to describe insulin regimes \[[@CR3]\]. Other terms used for regimes involving 3 or more injections per day are "multiple" and "intensified" insulin therapy. This drug-centered or pharmaceutical-based terminology served diabetology practitioners adequately in the past; the corresponding taxonomic methodology was able to incorporate the limited insulin preparations available, which included both traditional and modern insulins. This pharmaceutical classification of insulin regimes is not, however, syntaxic with the current emphasis on a patient-centered approach. It must be reemphasized here that it is patient-centeredness which forms the basis for recent advances in drug development and improvements in treatment guidelines.

Patient-Centered Insulin Taxonomy {#Sec3}
=================================

Most patients of diabetes do not appreciate the pharmacodynamic or kinetic nuances of insulin preparations. What is more relevant to the person requiring insulin is the number of injections to be taken per day, the timing of administration, and the flexibility with which these timings can be adjusted. Based upon these factors, it is important to craft a fresh synopsis of insulin regimes, using the number of injections per day as the framework for systematic study. At the same time, such a classification system must address the nature of insulin preparations, whether basal, premixed, or prandial.

Modern clinical trials are available which support the use of premixed insulin in once-daily and thrice-daily dosages, as opposed to the traditional twice-daily regime. The basal insulins detemir and glargine often need to be prescribed twice daily in order to achieve adequate glycemic control. Innovative regimes utilizing combinations of rapid-acting and premixed/coformulated insulins with varying frequencies of administration have also been documented. These factors also provide important reasons to revisit current classifications of insulin preparations.

Number-Based Classification of Insulin Regimes {#Sec4}
==============================================

While a number-based terminology has already been proposed \[[@CR4]\], it is inadequate to cover the current range of insulin preparations and the large number of regimens that they are used in. With the newer insulin analogues available, a modern, number-based classification is required. Table [1](#Tab1){ref-type="table"} lists the various insulin regimes and preparations as well as the frequency and timing of administration for each. All regimes enumerated in this table are backed by randomized controlled trials, as shown in Table [2](#Tab2){ref-type="table"}.Table 1Insulin preparations that are currently on the market, along with the prescription patterns for themFrequency of injectionName of regimenInsulin preparations usedTiming of administration1 (once a day)BasalNPH, IDet, IGlar, I glar U300At bedtime or the same time every dayBasalIDegAt any time of the dayPremixedBIAsp, LisproMixWith major mealCoformulationIDegAspWith major mealBasal + GLP1RAIDeg + liraglutide\
IGlar + lixisenatideAt any time of the day2 (twice a day)BasalNPH, IDet, IGlarAt bedtime and in the morningPremixedBHI, BIAsp, LisproMixWith major meals^a^CoformulationIDeg AspWith major meals^b^Basal plusBasal + prandialAt bedtime + with major meal3 (thrice a day)PrandialRegular, aspart, lispro, glulisineWith mealsBolus--bolus--premixedPrandial + premixedWith mealsPremixed--bolus--premixedPrandial + premixedWith mealsBolus-bolus--coformulationAspart + IDegAspWith meals4 or 5 (four or five times a day)Basal--bolusAny combination of basal and bolusWith meals \[[@CR3]\], and at bedtime or twice dailyCSI (continuous insulin infusion pump)Alternative to multiple injection^a^Antipodal meal (i.e., meals spaced roughly 12 h apart)^b^Minimum 8-h gap between 2 doses Table 2Prescription patterns of currently available insulin preparations, supported by evidence from various published clinical studiesInsulin preparation/frequency of injectionsOnce a dayTwice a dayThrice a dayMore than thrice a dayInsulin degludecZinman et al. Diabetes Care 2012. (BEGIN Once Long). T2DM patients (*n* = 1030) \[[@CR5]\]NANANAHeller et al. Lancet 2012. (BEGIN Basal--Bolus Type 1). T1DM patients (*n* = 629) \[[@CR6]\]NANANAInsulin glargine U 300Riddle et al. Diabetes Care 2014. Edition I. T2DM (*n* = 807) \[[@CR7]\]Yki-Jarvinen et al. Am Diabetes Assoc 2014. Edition II. (*n* = 811) \[[@CR8]\]Insulin glargineFritsche et al. Ann Intern Med 2003. T2DM (*n* = 695) \[[@CR9]\]Ashwell et al. Diabetes Medicine 2006. T1DM (*n* = 20) \[[@CR10]\]NANARiddle et al. Diabetes Care 2003. T2DM (*n* = 756) \[[@CR11]\]Hassan et al. Pediatrics 2008. T1DM (*n* = 19) \[[@CR12]\]NANAInsulin detemirKing. Diabetes Obes Metab 2009. T2DM (*n* = 29) \[[@CR13]\]Kolendorf et al. Diabetic Medicine 2006. T1DM (*n* = 130) \[[@CR14]\]NANARussell-Jones et al. Clin Ther 2004. T1DM (*n* = 749) \[[@CR15]\]Home et al. Diabetes Care 2004. T1DM (*n* = 408) \[[@CR16]\]NANAInsulin degludec + insulin aspartOnishi et al. Diabetes Obes Metab 2013. T2DM (*n* = 296) \[[@CR17]\]Fulcher et al. Diabetes Care 2014. Intensify premix I. T2DM (*n* = 446) \[[@CR18]\]NANAHirsch et al. Diabetes Care 2012. T1DM (*n* = 548) \[[@CR19]\]Kaneko et al. Diabetes Res Clin Pr 2015. Intensify all. T2DM (*n* = 424) \[[@CR20]\]NANABiAspYang et al. Curr Med Res Opin 2013. T2DM (*n* = 521) \[[@CR21]\]Raskin et al. Diabetes Care 2005. T2DM (*n* = 209) \[[@CR22]\]Garber et al. Diabetes Obes Metab 2005. The 1--2--3 study. T2DM (*n* = 100) \[[@CR23]\]NAKalra et al. Diabetes Res Clin Pr 2010. T2DM (*n* = 155) \[[@CR24]\]Yang et al. Diabetes Care 2008. T2DM (*n* = 321) \[[@CR25]\]Ligthelm et al. Exp Clin Endocrinol Diabetes 2006. T2DM (*n* = 394) \[[@CR26]\]NALisproMixKoivisto et al. Diabetes Care 1999. T2DM (*n* = 22) \[[@CR27]\]Roach et al. Clinical Therapeutics 2001. T2DM (*n* = 172) \[[@CR28]\]Jia et al. Lancet Diabetes Endocrinol 2015. T2DM (*n* = 402) \[[@CR29]\]NANATirgoviste et al. Rom J Intern Med 2003. T2DM (*n* = 175) \[[@CR30]\]NANABiphasic human insulinNAClements et al. Diabetes Obes Metab 2008. T1DM/T2DM (*n* = 664) \[[@CR31]\]Shanmugasundar et al. Indian J Med Res 2012. T2DM (*n* = 50) \[[@CR32]\]NANAMcNally et al. Diabetes Care 2007. T2DM (*n* = 160) \[[@CR33]\]NANAInsulin NPHRaskin et al. Diabetes Care 2000. T1DM (*n* = 619) \[[@CR34]\]Hassan et al. Pediatrics 2008. T1DM (*n* = 19) \[[@CR12]\]NARossetti et al. Diabetes Care 2003. T1DM (*n* = 51) \[[@CR35]\]Yki-Jarvinen et al. 2000. Diabetes Care. T2DM (*n* = 426) \[[@CR36]\]Rostami et al. Iran J Pediatr 2014. T1DM (*n* = 40) \[[@CR37]\]NANARegular human insulinNANAHome et al. Diabetes Research and Clinical Practice 2006. T1DM (*n* = 753) \[[@CR38]\]NANADanne et al. Pediatric Diabetes 2007. T1DM (*n* = 26) \[[@CR39]\]Insulin aspartMathieu et al. Diabetes Obes Metab 2014. T2DM (*n* = 413) \[[@CR40]\]NAGarber et al. Lancet 2012. T2DM (*n* = 1006) \[[@CR41]\]Bernard et al. Journal of Hospital Medicine 2011. T2DM (*n* = 176) \[[@CR42]\]Rodbard et al. Lancet 2013. (*n* = 401) \[[@CR43]\]NAUmpierrez et al. J Clin Endocrinol Metab 2009. T2DM (*n* = 130) \[[@CR44]\]NAInsulin lisproTinahones et al. Diabetes Obes Metab 2014. T2DM (*n* = 476) \[[@CR45]\]NABretzel et al. Lancet 2008. T2DM (*n* = 415) \[[@CR46]\]NANABowering et al. Diabet Med 2012. T2DM (*n* = 426) \[[@CR47]\]Insulin glulisineRiddle et al. Diabetes Obes Metab 2014. T2DM (*n* = 588) \[[@CR48]\]Ito et al. Drug Des Devel Ther 2014. T2DM (*n* = 27) \[[@CR49]\]Urata et al. J Ren Nutr 2015. T2DM (*n* = 18) \[[@CR50]\]Choe et al. Diabetes Metab J 2012. T2DM (*n* = 87) \[[@CR51]\]NAFritsche et al. Diabetes Obes Metab 2010. T2DM (*n* = 310) \[[@CR52]\]IDegLiraGough et al. Lancet Diabetes Endocrinol 2014. T2DM (*n* = 1663) \[[@CR53]\]NANANABuse et al. Diabetes Care 2014. T2DM (*n* = 413) \[[@CR54]\]NANANALixiLanRiddle et al. Diabetes Care 2013. T2DM (*n* = 446) \[[@CR55]\]NANANAAhren et al. Diabetes Care 2013. T2DM (*n* = 680) \[[@CR56]\]NANANA*Basal* NPH, glargine, detemir, degludec, *BHI* biphasic human insulin, *BIAsp* biphasic insulin aspart, *LisproMix* biphasic insulin lispro, *IAsp* insulin aspart, *IDeg* insulin degludec, *IDegAsp* insulin degludec and insulin aspart, *IDegLira* insulin degludec and liraglutide, *LixiLan* lixisenatide and insulin glargine, *IDet* insulin detemir, *IGlar* insulin glargine, *IGlu* insulin glulisine, *NPH* neutral protamine Hagedorn, *Prandial* regular, lispro, aspart, glulisine, *NA* not applicable

Newer ultralong-acting basal insulins and coformulations of ultralong-acting insulin analogues with either rapid-acting insulin analogues, or with GLP-1RA (glucagon-like peptide-1 receptor agonists), have recently been introduced. While these newer preparations are a combination of two preparations, they definitely do not fit into the earlier category of premixed insulins. They differ from previous molecules in their kinetic properties as well as their versatility. Other molecules, such as PEGylated lispro, are also in advanced stages of development, and will soon be available for clinical use.

Once-daily injections include all basal, premixed, and coformulation insulins. If necessary, these can be used in a twice-daily regime. Basal insulins were initially thought to be used once a day. As NPH, glargine, and detemir do not provide adequate 24 h coverage, they may need to be used twice daily in certain patients, especially those with type 1 diabetes. The novel ultralong-acting insulin degludec provides adequate 24-h glycemic control and can be used once daily at any time of the day. These factors need to be reflected in an updated taxonomic profile of insulin.

While basal insulins are able to achieve adequate fasting control in many cases, they are unable to provide prandial coverage. Initiation of a once-daily premix or coformulation with the major meal or meal with highest glycemic excursion allows control of postprandial glucose after one meal as well. The frequency of administration of these insulin preparations can, if required, be intensified to twice or thrice daily. While biphasic human insulin or premixed analogue insulin need to be administered at antipodal meals (i.e., meals spaced roughly 12 h apart), IDegAsp (insulin degludec aspart) may be administered at two consecutive meals, provided an 8-h gap is maintained. All of these patterns of use find a place in a number-based umbrella of insulin taxonomy, as opposed to the traditional regime classification, which proposes only twice daily use of premixed insulin.

If the twice-daily regime does not achieve 24-h euglycemia, intensive insulin therapy (defined as that including 3 or more than 3 injections per day) may be required in the form of either three premix insulin injections or a basal bolus regimen. Various regimes are available in this group. Depending upon the needs of the patient, one can prescribe prandial insulin thrice a day; premixed twice and prandial once; or prandial twice and premixed/coformulation once. Basal--bolus regimes involving 3 bolus doses and 1 or 2 basal doses can also be used in refractory patients and in type 1 diabetes.

Conclusion {#Sec5}
==========

The number-based taxonomy is able to include all of these regimes as subclasses (Table [1](#Tab1){ref-type="table"}), based upon published randomized controlled trials (Table [2](#Tab2){ref-type="table"}). This arrangement makes it much simpler for the student to understand the subject of insulin pharmacotherapeutics. It helps the practitioner to appreciate the versatility of insulin and the many ways in which this life-saving molecule can be used. This system also allows the physician to choose the appropriate regime for a particular patient while following person-centeredness in letter and spirit. At the same time, choice of regime should take biomedical factors such as severity of hyperglycemia, risk of hypoglycemia, and diabesity indices into account.

Such a codification would promote appropriate choice of therapy based upon the individual's glucophenotype, motivation level, and psychosocial limitations, ease of use, and acceptance of insulin, by sensitizing the diabetes care professional to the patient's needs. It also facilitates the gradual intensification of therapy with the same insulin.

We therefore propose that future guidelines and recommendations utilize this person-centered arrangement of insulin regimes, rather than straitjacketing preparations according to traditional criteria.

No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Conflict of interest {#d29e1321}
====================

S. Kalra has received speaker/advisory fees from Eli Lilly, Novo Nordisk, and Sanofi--Aventis in the recent past. Y. Gupta declares no conflict of interest.

Compliance with ethics guidelines {#d29e1326}
=================================

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Open Access {#d29e1331}
===========

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
